Frederic W. Selck, PhD

Frederic W. (Fred) Selck specializes in performing empirical and statistical analyses, applying theoretical models, conducting market analysis and research, and analyzing the impact of public policy programs. Dr. Selck’s expertise includes a deep understanding of Medicare and Medicaid, third-party health plans, pharmaceuticals, and medical devices. He has applied his expertise in the life sciences and healthcare industries and has been involved in matters dealing with competition, intellectual property, and anti-kickback and off-label marketing allegations.

Prior to joining Bates White, Dr. Selck was a Senior Service Fellow at the National Center for Health Statistics and a steering committee member of the Health Economics Research Group at the Centers for Disease Control and Prevention. He has taught graduate-level courses in microeconomics and health economics at Johns Hopkins University and has published in peer-reviewed journals such as Health Services Research, Statistics in Medicine, and Annals of Surgery.

PhD, Applied Economics, Johns Hopkins University

MA, Economics, City University of New York, Hunter College

BA, Economics, City University of New York, Hunter College

• Serving as lead consulting expert for plaintiffs in a matter involving allegations of anticompetitive conduct by a pharmaceutical manufacturer. 
• Serving as the lead consulting expert for a top US medical school and healthcare provider in estimating the research and business losses occurring after a natural disaster.
• Supported the expert in analyzing the impact of the “Cadillac tax” section of the Affordable Care Act (scheduled to be implemented in 2020) on employer and employee choices regarding insurance options, healthcare spending, and federal revenue. 
• On behalf of the plaintiff in Wells Fargo Bank et al. v. Merrimack Pharmaceuticals, Inc., co-led the team supporting the expert and performed a valuation of Merrimack’s pipeline of oncology drugs that supported the opinion that the sale of Merrimack’s sole commercial product constituted a fundamental change of the company.
• In Pharmaceutical Solutions, Inc. (VetSource) v. Nevada State Board of Pharmacy et al., supported the expert testifying on behalf of VetSource in analyzing whether VetSource’s home delivery of pet medications directly competes with retail pharmacies in Nevada.  
• In Amgen Inc. v. Sanofi Aventisub LLC and Regeneron Pharmaceuticals, Inc., served as a consulting expert supporting the testimony of Dr. Ernst R. Berndt regarding the eBay factors in a matter involving permanent injunction on behalf of Amgen, alleging infringement of its patents.  
• In United States v. Novartis Pharmaceuticals Corp. and BioScrip, Inc., provided consulting expertise for Novartis on the economics of pharmacy dispensing, government reimbursements, and adherence in connection with alleged FCA violations associated with alleged kickbacks concerning Novartis’s distribution of two specialty brand-name pharmaceuticals: Myfortic and Exjade.
• In United States ex rel. Kevin N. Colquitt v. Abbott Labs, Inc., provided support for expert analyses in connection with alleged off-label promotion of certain medical devices that violated the FCA.